子宫内膜癌靶向药物治疗研究进展  

Advances in targeted drug therapy for endometrial carcinoma

作　　者：曹海敬 薛嫚[1] 李芳[1] 俸灵林[1] 丁宏 张婷[1] CAO Hai-jing;XUE Man;LI Fang;FENG Ling-lin;DING Hong;ZHANG Ting(National Health Commission Key Lab of Reproduction Regulation/Shanghai Engineering Research Center of Reproductive Health Drug and Devices,Shanghai Institute of Planned Parenthood Research,SHANGHAI 200032,China;State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Science,SHANGHAI 201203,China)

机构地区：[1]上海市计划生育科学研究所国家卫生健康委员会计划生育药具重点实验室/上海生殖健康药具工程技术研究中心,上海200032 [2]中国科学院上海药物研究所新药研究国家重点实验室,上海201203

出　　处：《中国新药与临床杂志》2020年第1期1-7,共7页Chinese Journal of New Drugs and Clinical Remedies

基　　金：中国科学院上海药物研究所新药研究国家重点实验室开放课题（SIMM1803KF-04）

摘　　要：子宫内膜癌的化疗耐药性问题显著,迫切需要新的治疗方案。随着对肿瘤发病机制和信号传导通路的深入研究,以及表观遗传修饰作用机制的阐明,靶向药物研究为子宫内膜癌的治疗提供了新的方法和手段。本文综述了表皮生长因子受体拮抗剂、血管内皮生长因子抑制剂、PI3K/Akt/mTOR通路抑制剂、PD-1/PD-L1抑制剂和表观遗传修饰抑制剂等靶向药物在子宫内膜癌治疗领域的研究进展,为临床用药提供新思路。The problem of chemoresistance of endometrial cancer is obvious, so new treatment is urgently needed. With the in-depth study of tumor pathogenesis and signal transduction pathway, as well as the explanation of epigenetic modification mechanism,targeted drug research provides new methods and means for the treatment of endometrial cancer. This article reviewed the research progress of epidermal growth factor receptor antagonists, vascular endothelial growth factor inhibitors, PI3K/Akt/mTOR pathway inhibitors, PD-1/PD-L1 inhibitors and epigenetic modification inhibitors in the field of endometrial cancer treatment, and provides new ideas for clinical medication.

关 键 词：子宫内膜肿瘤 分子靶向治疗 表观基因组学 

分 类 号：R737.33[医药卫生—肿瘤] R979.1[医药卫生—临床医学]